April 30, 2018
Mylan Australia’s Country Manager has been elected chair of the Generic and Biosimilar Medicines Association (GBMA), a group representing generic and biosimilar medicine suppliers throughout Australia. Sylvain Vigneault brings more than 25 years of pharmaceutical experience to the role, including two years as a member of the GBMA.
Mylan is the leading supplier by volume of prescription medicines in Australia and continues to invest in a growing presence in biosimilars. In line with Mylan’s mission to provide high quality medicine to the world’s 7 billion people, the GBMA advocates for policies that increase adoption of biosimilars and works to ensure the sustainability of the sector through competition and innovation.
Vigneault began his career in the pharmaceutical industry in Canada in 1993 at a small privately-owned company. He went on to work in the Czech Republic, France, Germany, Switzerland and Singapore. In 2012, he was appointed General Manager Australia and New Zealand for Abbott EPD, based in Sydney, Australia. Mylan acquired that business in 2015, and Vigneault was appointed Mylan Country Manager in Australia in 2016.
Read the press release from the GBMA announcing Vigneault’s appointment here.